Literature DB >> 6145781

Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone.

V Petrow, G M Padilla, S Mukherji, S A Marts.   

Abstract

Growth of the Dunning R3327-H prostatic adenocarcinoma, implanted in the rat, is inhibited by 6-methylene progesterone. This compound is a potent inhibitor of rat prostatic 5-alpha-reductase and in-vivo produced marked involution of the prostate. Thus the tumor requires dihydrotestosterone and not testosterone for growth.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145781     DOI: 10.1111/j.2042-7158.1984.tb04395.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer.

Authors:  S Vijayakumar; S F Quadri; L Dong; L Ignacio; I N Kathuria; H Sutton; H Halpern
Journal:  J Natl Med Assoc       Date:  1995-11       Impact factor: 1.798

2.  5-α reductase inhibitors and prostate cancer prevention: where do we turn now?

Authors:  Robert J Hamilton; Stephen J Freedland
Journal:  BMC Med       Date:  2011-09-15       Impact factor: 8.775

Review 3.  Epidemiology of Prostate Cancer.

Authors:  Prashanth Rawla
Journal:  World J Oncol       Date:  2019-04-20

4.  Current status of 5α-reductase inhibitors in prostate disease management.

Authors:  Dong Il Kang; Jae Il Chung
Journal:  Korean J Urol       Date:  2013-04-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.